NEWS

  • Saphetor signs agreement with Geneva University Hospitals

    Saphetor signs agreement with Geneva University Hospitals to deploy its platform for advanced NGS analysis

    Lausanne, Switzerland – September 15, 2016 – Saphetor, the leading European company in genome-scale analysis based on next generation sequencing (NGS), announced today that it has signed an agreement with the Geneva University Hospitals (HUG) to supply its Division of Genetic Medicine, headed by Professor Stylianos E. Antonarakis, with comprehensive and accurate analysis of their NGS data. Prof. Antonarakis is also Director of the Department of Genetic Medicine and Development at the University of Geneva (UNIGE) Faculty of Medicine, Director of the iGE3 institute of Genetics and Genomics, and President of the Human Genome Organization. Under the agreement, Prof. Antonarakis’ team will apply Saphetor’s precision medicine platform for clinical use. HUG has chosen to install Saphetor’s software and data solution in-house.

    Prof. Antonarakis’s team is recognized worldwide as one of the leading clinical research groups in genetic medicine. The integration of Saphetor’s cutting-edge NGS analysis capabilities into their daily clinical routine will allow his group to accelerate and expand its efforts in diagnosing and studying genetic diseases. As one of the largest academic hospitals in Switzerland, HUG is investing in scaling up its services in personalized medicine and make it accessible to all patients.

    Prof. Antonarakis said: “In our Genome Clinic we handle an ever increasing number of cases that require processing of enormous amounts of high throughput sequencing data to discover pathogenic variants in hereditary disorders and cancer. Saphetor’s sophisticated algorithms mine billions of data points and present the result in an easy to navigate interface that assists us to reliably and accurately diagnose and treat patients.”

    Andreas Massouras, CEO of Saphetor, said: “Prof. Antonarakis is without a doubt one of the foremost experts in genetic medicine, and has been making major contributions to its application in clinical practice. We are honored by his confidence in Saphetor’s ability to further the aims of the highly innovative Genome Clinic in diagnosing complex disorders and proposing novel treatment strategies to patients in Switzerland and abroad.”

    Saphetor develops software and sophisticated analytical processes to identify genetic variants with greater accuracy and to give its clients access to seamlessly integrated data from a rapidly growing collection of genetic databases. To date, Saphetor has already aggregated more than 18 billion genetic variant annotations from a wide range of databases. Saphetor’s competitive advantage is its unique ability to combine data integration with annotation and interpretation in an interface that is intuitive and easy to navigate.

    About Saphetor

    Founded in 2014, Saphetor is a precision medicine company at the cutting edge of genome-scale analysis based on Next Generation Sequencing (NGS). Capitalizing on the emerging trend in NGS to use large “panels” of genes, exomes, or whole genomes, Saphetor’s suite of services offers researchers and clinicians intuitive, data-driven solutions to make faster, more accurate diagnoses and informed decisions for the selection of the best therapies, especially for cancer and difficult to diagnose conditions, such as rare diseases or cognitive impairment. For more information: www.saphetor.com

     

    The HUG: Care, Teaching and Research

    The Geneva University Hospitals (HUG), a reference academic institution in Switzerland and abroad, comprises eight public hospitals of Geneva with centers of excellence in hepato-biliary and pancreatic disease, cardiovascular disease, oncology, musculoskeletal and sports medicine, geriatrics, genetic medicine and vaccinology. With its 10,500 employees, HUG each year treats 60,000 hospitalized patients, handles 91,000 emergencies, 990,000 consultations or ambulatory patients, and 26,000 surgical procedures. More than 800 physicians, 3,000 interns and 150 apprentices work and perform their training here. The HUG is working closely with the Faculty of Medicine of the University of Geneva and the World Health Organization in various training and research projects. HUG has partnerships with CHUV, EPFL, CERN and other actors in the Lake Geneva Health Valley. The annual budget of HUG is 1.8 billion Swiss francs.

     

    More information on:

     

    For further enquiries:

    Andreas Massouras, PhD
    Chief Executive Officer
    +41 21 552 09 77
    andreas.massouras@saphetor.com

    Hans Herklots (media)
    Capricorn One
    +41 79 598 7149
    capricorn1@bluewin.ch

  • Saphetor’s performance at Precision FDA Challenge


    Lausanne, Switzerland – May 02, 2016 – Saphetor participated in the Precision FDA Challenge. This is an initiative by the Food and Drug Administration, the US regulator for health care, which is seeking effective ways to regulate the emerging molecular data industry. In this challenge, participants submitted whole-genome variant lists from their variant discovery methods which were evaluated and compared by the FDA.

    We are pleased to announce that our results were among the best, as witnessed by an F-score of more than 99% (see below). This is proof of our ongoing commitment to excellence and continuous improvement of the services we provide.

    Saphetor Performance Precision Medicine FDA

    If you would like to learn more about this initiative, please look at https://precision.fda.gov/, where you can also obtain results from other participants in the US, Europe (including Switzerland), and elsewhere.

    The Saphetor Team

  • Saphetor signs collaboration with Lausanne University Hospital (CHUV)

    Agreement covers analysis of CHUV NGS data in research and clinical applications for endocrinology, metabolism and diabetes.

    Lausanne, Switzerland – April 20, 2016 – Saphetor SA, a Swiss precision medicine company working at the cutting edge of clinically meaningful genome-scale analysis based on Next Generation Sequencing (NGS), announced today that it has signed a collaboration agreement with the department of endocrinology, diabetes and metabolism of the Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois or CHUV), headed by Prof. Dr. Nelly Pitteloud. Under the agreement, Prof. Pitteloud’s department will use Saphetor’s precision medicine platform in research and clinical applications.
    Prof. Pitteloud said: “The genetics underlying the multiple endocrine disorders that we research, diagnose and treat are extremely complex. The vast amount of NGS data that we generate through our research holds the key to significantly advance our understanding of these diseases, our ability to diagnose them, and contributes to the development of improved and tailored treatments. We believe that the analytical capabilities of Saphetor’s powerful and sophisticated next generation sequencing platform will help us find the key to many of these underserved diseases.”
    Prof. Pitteloud focuses on translational research in the neuroendocrine and gonadal control of human reproduction, and the links between metabolism and reproduction. Her work on gonadotropin-releasing hormone (GnRH) deficiency has led to a number of landmark studies in the New England Journal of Medicine, the British Medical Journal, the Proceedings of the National Academy of Sciences, and several specialized research journals.
    Andreas Massouras, CEO of Saphetor, said: “We are proud to start working with Professor Pitteloud, who is a leader in her field, and look forward to enable her team to further elucidate the genetic causes of GnRH deficiency and other endocrine disorders.”
    Saphetor develops software and sophisticated analytical processes, using proprietary algorithms and trade secret know-how to identify genetic variants with greater accuracy and to give its clients access to seamlessly integrated data from a rapidly growing collection of genetic databases. To date, Saphetor has already aggregated more than 20 leading databases, representing more than 13 billion genetic variant annotations. Saphetor’s competitive advantage is its unique ability to combine data integration with annotation and interpretation in an interface that is intuitive and easy to navigate

    About Saphetor

    Founded in 2014, Saphetor is a precision medicine company at the cutting edge of genome-scale analysis based on Next Generation Sequencing (NGS). Capitalizing on the emerging trend in NGS to use large “panels” of genes, exomes, or whole genomes, Saphetor’s suite of services offers clinicians intuitive, data-driven solutions to make faster, more accurate diagnoses, and informed decisions for the selection of the best therapies, especially for cancer and difficult to diagnose conditions, such as rare diseases or cognitive impairment. For more information: www.saphetor.com

    For further enquiries:
    Andreas Massouras, PhD
    Chief Executive Officer
    +41 21 693 8925
    andreas.massouras@saphetor.com

    Hans Herklots (media)
    Capricorn One
    +41 79 598 7149
    capricorn1@bluewin.ch

    Also on the web:
    Yahoo Finance News
    Business Wire
    Finanznachrichten
    Agefi
    Labiotech

  • Saphetor Raises CHF1.2 Million in Seed Financing Round

    Lausanne, Switzerland – February 17, 2016 – Saphetor SA, a Swiss precision medicine company working at the cutting edge of clinically meaningful genome-scale analysis based on Next Generation Sequencing (NGS), announced today that it successfully completed a CHF 1.2 million seed financing round from a group of undisclosed investors.
    Andreas Massouras, CEO of Saphetor, said: “We are delighted with the closing of the seed financing round. The proceeds will allow us to further develop our advanced NGS analysis capabilities, and expand our network of commercial and research collaborations in Europe and beyond well into 2017. We have built a decision support platform that offers information of unprecedented depth and detail to professionals in clinical genetics research and medical diagnostics to help them make informed decisions, and that is intuitive and easy to use.”
    Saphetor develops software and sophisticated analytical processes, using proprietary algorithms and trade secret know-how to identify genetic variants with greater accuracy and to give its clients access to seamlessly integrated data from a rapidly growing collection of genetic databases. To date, Saphetor has already aggregated 20 leading databases, representing more than 10 billion genetic variant annotations. Saphetor’s competitive advantage is its unique ability to combine data integration with annotation and interpretation in an interface that is intuitive and easy to navigate.

    About Saphetor

    Founded in 2014, Saphetor is a precision medicine company at the cutting edge of genome-scale analysis based on Next Generation Sequencing (NGS). Capitalizing on the emerging trend in NGS to use large “panels” of genes, exomes, or whole genomes, Saphetor’s suite of services offers clinicians intuitive, data-driven solutions to make faster, more accurate diagnoses, and informed decisions for the selection of the best therapies, especially for cancer and difficult to diagnose conditions, such as rare diseases or cognitive impairment. For more information: www.saphetor.com

    For further enquiries:
    Andreas Massouras, PhD
    Chief Executive Officer
    +41 21 693 8925
    andreas.massouras@saphetor.com

    Hans Herklots (media)
    Capricorn One
    +41 79 598 7149
    capricorn1@bluewin.ch

    Also on the web:
    Start-up ticker.ch
    Business wire

EVENTS

  • The AMERICAN SOCIETY of HUMAN GENETICS Annual Meeting in Vancouver 18-22 October 2016

    The Saphetor team will be present at the ASHG annual meeting  2016 in Vancouver between 18-22 of October 2016. Please visit us at Booth 324

  • Personalized Medicine World Congress 2016

    Meet Our CEO at PMWC between 24-27 January in Mountain View

Tweets

 

https://twitter.com/Labiotech_eu/status/724134576726134784